Zai Lab Announces Pricing of Hong Kong Secondary Listing - SC Read more about Zai Lab Announces Pricing of Hong Kong Secondary Listing - SC
则乐®用于中国铂敏感复发卵巢癌患者维持治疗的3期临床研究NORA证实无论生物标记物状态如何个体化起始剂量治疗方案都能显著改善PFS并提高安全性 Read more about 则乐®用于中国铂敏感复发卵巢癌患者维持治疗的3期临床研究NORA证实无论生物标记物状态如何个体化起始剂量治疗方案都能显著改善PFS并提高安全性
Zai Lab to Announce Financial Results for the Six Months Ended June 30, 2020 and Corporate Updates - SC Read more about Zai Lab to Announce Financial Results for the Six Months Ended June 30, 2020 and Corporate Updates - SC